Delcath Systems Announces Publication Of An Independent Study Conducted By Investigators At The University Hospital Of Leipzig, Germany, Titled "Hepatic Chemosaturation With Melphalan In Patients With Primary Or Secondary Liver Tumors With Or Without Extrahepatic Tumor Manifestation,"
Portfolio Pulse from Benzinga Newsdesk
Delcath Systems announced the publication of an independent study on its CHEMOSAT Hepatic Delivery System, showing high efficacy and safety in treating liver tumors. The study reported a 91% disease control rate and highlighted the importance of repeated treatments.
August 26, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Delcath Systems' CHEMOSAT Hepatic Delivery System demonstrated high efficacy and safety in an independent study, with a 91% disease control rate in liver cancer patients. The study supports the use of repeated treatments for long-term disease control.
The independent study published in a reputable journal highlights the efficacy and safety of Delcath's CHEMOSAT system, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100